Bone formation regulates circulating concentrations of fibroblast growth factor 23

Endocrinology

Volumn 150, Issue 11, 2009, Pages 4835-4845

  Samadfam, Rana ^a   Richard, Christian ^a   Nguyen Yamamoto, Loan ^a   Bolivar, Isabel ^a   Goltzman, David ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCIUM; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE[1-34]; SODIUM PHOSPHATE COTRANSPORTER 2A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE REMODELING; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ANIMALS; BONE AND BONES; CELL LINE; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOGENESIS; VITAMIN D;

EID: 70350330869     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-0472     Document Type: Article

References (53)

1. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505 (Pubitemid 32488266)
2. Liu S, Zhou J, Tang W, Menard R, Feng JQ, Quarles LD 2008 Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab 295:E254-E261
3. Bai XY, Miao D, Goltzman D, Karaplis AC 2003 The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843-9849 (Pubitemid 36800487)
4. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Jüppner H, Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087-3094 (Pubitemid 38829975)
5. Bai X, Miao D, Li J, Goltzman D, Karaplis AC 2004 Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145:5269-5279 (Pubitemid 39551149)
6. Berndt TJ, Schiavi S, Kumar R 2005 "Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 289:F1170-F1182
7. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561-568 (Pubitemid 38542505)
8. Schiavi SC 2006 Bone talk. Nat Genet 38:1230-1231
9. The ADHR Consortium 2000 Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348
10. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663 (Pubitemid 36459471)
11. Weber TJ, Liu S, Indridason OS, Quarles LD 2003 Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227-1234 (Pubitemid 37294915)
12. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960 (Pubitemid 35316332)
13. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505 (Pubitemid 32488266)
14. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Jüppner H, Econs MJ 2001 The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497-500 (Pubitemid 32207449)
15. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692 (Pubitemid 38057709)
16. Benet-Pagès A, Orlik P, Strom TM, Lorenz-Depiereux B 2005 An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385-390 (Pubitemid 40220655)
17. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE 2005 A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 90:2424-2427 (Pubitemid 40586293)
18. Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yoshii N, Yamazaki Y, Yamashita T, Silver J, Igarashi T, Fujita T 2005 A novel mutation in fibroblast growth factor (FGF)23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90:5523-5527 (Pubitemid 41415453)
19. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Zelikovic I, Raimer S, Metzker A, Richard G, Sprecher E 2004 Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36:579-581 (Pubitemid 38715983)
20. Razzaque MS, Sitara D, Taguchi T, St-Arnaud R, Lanske B 2006 Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 20:720-722 (Pubitemid 46671193)
21. Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR, Ghishan FK 2005 1α,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289:G1036-G1042
22. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA 2005 Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146:5358-5364 (Pubitemid 41653049)
23. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE 2005 Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 36:971-977 (Pubitemid 40797997)
24. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T 2005 Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289:F1088-F1095 (Pubitemid 41447065)
25. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE 2006 Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315 (Pubitemid 44646294)
26. Lorenz-Depiereux B, Bastepe M, Benet-Pagès A, Amyere M, Wagenstaller J, Müller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Jüppner H, Strom TM 2006 DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248-1250 (Pubitemid 44646286)
27. Tartaix PH, Doulaverakis M, George A, Fisher LW, Butler WT, Qin C, Salih E, Tan M, Fujimoto Y, Spevak L, Boskey AL 2004 In vitro effects of dentin matrix protein-1 on hydroxyapatite formation provide insights into in vivo functions. J Biol Chem 279:18115-18120
28. Gajjeraman S, Narayanan K, Hao J, Qin C, George A 2007 Matrix macromolecules in hard tissues control the nucleation and hierarchical assembly of hydroxyapatite. J Biol Chem 282:1193-1204 (Pubitemid 47076548)
29. Lu Y, Qin C, Xie Y, Bonewald LF, Feng JQ 2009 Studies of the DMP1 57-kDa functional domain both in vivo and in vitro. Cells Tissues Organs 189:175-185
30. Liu S, Zhou J, Tang W, Menard R, Feng JQ, Quarles LD 2008 Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab 295:E254-E261
31. Luckman SP, Hughes DE, Coxon FP, Russell GG, Rogers MJ 2005 JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 7:1265-1274
32. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176 (Pubitemid 28180851)
33. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to RANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602 (Pubitemid 28173173)
34. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441 (Pubitemid 32402100)
35. Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, Hendy GN, Goltzman D 2001 Targeted ablation of the 25-hydroxyvitamin D 1α-hydroxylase enzyme: evidence for skeletal, reproductive and immune dysfunction. Proc Natl Acad Sci USA 98:7498-7503 (Pubitemid 32567977)
36. Samadfam R, Xia Q, Goltzman D 2007 Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 22:55-63 (Pubitemid 46032597)
37. Samadfam R, Xia Q, Goltzman D 2007 Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. Endocrinology 148:2778-2787 (Pubitemid 46984814)
38. Panda DK, Miao D, Bolivar I, Li J, Huo R, Hendy GN, Goltzman D 2004 Inactivation of the 25-hydroxyvitamin D 1α-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 279:16754-16766 (Pubitemid 38509378)
39. Miao D, Bai X, Panda D, McKee M, Karaplis A, Goltzman D 2001 Osteomalacia in Hyp mice is associated with abnormal Phex expression and with altered bone matrix protein expression and deposition. Endocrinology 142:926-939 (Pubitemid 32222443)
40. 3 in vivo. BMC Musculoskelet Disord 3:16-26
41. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
42. Dardenne O, Prud'homme J, Hacking SA, Glorieux FH, St-Arnaud R 2003 Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1). Bone 32:332-340
43. Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, Baron R, Demay MB 1999 Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 140:4982-4987 (Pubitemid 30687103)
44. Prentice A, Ceesay M, Nigdikar S, Allen SJ, Pettifor JM 2008 FGF23 is elevated in Gambian children with rickets. Bone 42:788-797
45. O'Brien CA, Jilka RL, Fu Q, Stewart S, Weinstein RS, Manolagas SC 2005 IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab 289:E784-E793 (Pubitemid 41504377)
46. Sitara D, Razzaque MS, St-Arnaud R, Huang W, Taguchi T, Erben RG, Lanske B 2006 Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 169:2161-2170 (Pubitemid 351181975)
47. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Jüppner H, Salusky IB 2009 Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94:511-517
48. Quarles LD 2008 Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118:3820-3828
49. Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO, Lane NE 2008 Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 58:3485-3497
50. Friedman MS, Oyserman SM, Hankenson KD 2009 Wnt11 promotes osteoblast maturation and mineralization through R-spondin 2. J Biol Chem 284:14117-14125
51. Kulkarni GV, Chen B, Malone JP, Narayanan AS, George A 2000 Promotion of selective cell attachment by the RGD sequence in dentine matrix protein 1. Arch Oral Biol 45:475-484 (Pubitemid 30262645)
52. Narayanan K, Srinivas R, Ramachandran A, Hao J, Quinn B, George A 2001 Differentiation of embryonic mesenchymal cells to odontoblast-like cells by overexpression of dentin matrix protein 1. Proc Natl Acad Sci USA 98:4516-4521 (Pubitemid 32295008)
53. Almushayt A, Narayanan K, Zaki AE, George A 2006 Dentin matrix protein 1 induces cytodifferentiation of dental pulp stem cells into odontoblasts. Gene Ther 13:611-620